Correlation Between Eledon Pharmaceuticals and Citius Oncology,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eledon Pharmaceuticals and Citius Oncology, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eledon Pharmaceuticals and Citius Oncology, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eledon Pharmaceuticals and Citius Oncology,, you can compare the effects of market volatilities on Eledon Pharmaceuticals and Citius Oncology, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eledon Pharmaceuticals with a short position of Citius Oncology,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eledon Pharmaceuticals and Citius Oncology,.

Diversification Opportunities for Eledon Pharmaceuticals and Citius Oncology,

-0.38
  Correlation Coefficient

Very good diversification

The 3 months correlation between Eledon and Citius is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Eledon Pharmaceuticals and Citius Oncology, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Citius Oncology, and Eledon Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eledon Pharmaceuticals are associated (or correlated) with Citius Oncology,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Citius Oncology, has no effect on the direction of Eledon Pharmaceuticals i.e., Eledon Pharmaceuticals and Citius Oncology, go up and down completely randomly.

Pair Corralation between Eledon Pharmaceuticals and Citius Oncology,

Given the investment horizon of 90 days Eledon Pharmaceuticals is expected to generate 0.57 times more return on investment than Citius Oncology,. However, Eledon Pharmaceuticals is 1.74 times less risky than Citius Oncology,. It trades about 0.26 of its potential returns per unit of risk. Citius Oncology, is currently generating about 0.06 per unit of risk. If you would invest  275.00  in Eledon Pharmaceuticals on September 12, 2024 and sell it today you would earn a total of  208.00  from holding Eledon Pharmaceuticals or generate 75.64% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Eledon Pharmaceuticals  vs.  Citius Oncology,

 Performance 
       Timeline  
Eledon Pharmaceuticals 

Risk-Adjusted Performance

17 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Eledon Pharmaceuticals are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, Eledon Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.
Citius Oncology, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Citius Oncology, has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Eledon Pharmaceuticals and Citius Oncology, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eledon Pharmaceuticals and Citius Oncology,

The main advantage of trading using opposite Eledon Pharmaceuticals and Citius Oncology, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eledon Pharmaceuticals position performs unexpectedly, Citius Oncology, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will offset losses from the drop in Citius Oncology,'s long position.
The idea behind Eledon Pharmaceuticals and Citius Oncology, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments